Medical Pharmacology: Chapter 27 — Gastrointestinal Pharmacology -- Module 4 — Inflammatory Bowel Disease Pharmacology, Part 2: Biologics and Small Molecules

Chapter 27 — Gastrointestinal Pharmacology — Module 4 — Inflammatory Bowel Disease Pharmacology, Part 2: Biologics and Small Molecules

1. Anti-tumor necrosis factor (anti-TNF) biologics were the first targeted therapies approved for inflammatory bowel disease (IBD). What is the fundamental pharmacological action shared by all anti-TNF agents used in IBD?

A) They neutralize soluble and membrane-bound TNF-alpha, a central pro-inflammatory cytokine in both ulcerative colitis and Crohn's disease
B) They block the alpha-4-beta-7 integrin on gut-homing lymphocytes, preventing migration to the intestinal mucosa
C) They inhibit intracellular Janus kinase (JAK)-STAT signaling downstream of multiple cytokine receptors
D) They bind the p40 subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23)
E) They selectively block the interleukin-23 (IL-23) p19 subunit while sparing IL-12

ANSWER: A

Rationale:

Anti-TNF biologics neutralize both soluble and transmembrane TNF-alpha, a central pro-inflammatory cytokine driving mucosal inflammation in both ulcerative colitis and Crohn's disease. This shared mechanism defines the class, and TNF neutralization underlies both their efficacy and their characteristic infection risks.

Option B: Option B describes vedolizumab, a gut-selective integrin blocker, not an anti-TNF mechanism.
Option C: Option C describes the JAK inhibitors, which are oral small molecules acting intracellularly rather than neutralizing an extracellular cytokine.
Option D: Option D describes ustekinumab, which targets the shared IL-12/IL-23 p40 subunit.
Option E: Option E describes risankizumab, a selective IL-23 p19 inhibitor; neither D nor E neutralizes TNF-alpha.

2. A patient with Crohn's disease is started on infliximab. Among the anti-TNF agents, infliximab is structurally distinct in a way that increases its immunogenicity. Which description correctly characterizes the infliximab molecule?

A) A fully human IgG1 monoclonal antibody administered subcutaneously
B) A PEGylated Fab' fragment that lacks the fragment crystallizable (Fc) region
C) A small molecule oral inhibitor of Janus kinase (JAK)-STAT signaling
D) A chimeric (approximately 25% murine, 75% human) IgG1 monoclonal antibody administered by intravenous infusion
E) A humanized IgG1 monoclonal antibody directed against the alpha-4-beta-7 integrin

ANSWER: D

Rationale:

Infliximab is a chimeric IgG1 monoclonal antibody, roughly 25% murine and 75% human, given by intravenous infusion. The murine component makes it more immunogenic than fully human anti-TNF agents, and anti-drug antibodies directed against that murine portion are the primary mechanism of secondary loss of response.

Option A: Option A describes adalimumab, a fully human subcutaneous agent.
Option B: Option B describes certolizumab pegol, a PEGylated Fab' fragment lacking the Fc region.
Option C: Option C describes a JAK inhibitor, which is not an antibody at all.
Option E: Option E describes vedolizumab, an anti-integrin antibody rather than an anti-TNF agent.

3. A woman with Crohn's disease who requires continued anti-TNF therapy is planning pregnancy. One anti-TNF agent is preferred in the third trimester because its structure prevents transfer across the placenta. Which agent is it, and why?

A) Adalimumab, because its fully human structure eliminates placental transfer
B) Certolizumab pegol, because it is a PEGylated Fab' fragment lacking the fragment crystallizable (Fc) region and therefore cannot cross the placenta via the neonatal Fc receptor
C) Infliximab, because intravenous dosing allows precise control of maternal serum levels
D) Golimumab, because its monthly maintenance schedule minimizes fetal exposure
E) Tofacitinib, because oral small molecules are cleared before reaching the fetal circulation

ANSWER: B

Rationale:

Certolizumab pegol is a PEGylated Fab' fragment of a humanized anti-TNF antibody that lacks the Fc region. Because placental transfer of IgG in the third trimester is mediated by the neonatal Fc receptor, the absence of an Fc region means certolizumab does not cross the placenta appreciably, making it the preferred anti-TNF agent when therapy must continue late in pregnancy.

Option A: Option A incorrectly states that adalimumab eliminates placental transfer; despite being fully human, adalimumab is a complete IgG1 antibody that does transfer across the placenta in the third trimester.
Option C: Option C is incorrect because infliximab is a full IgG1 antibody that crosses the placenta; route of administration does not prevent transfer.
Option D: Option D is incorrect because golimumab is also a full IgG1 antibody and its dosing interval does not address placental transfer.
Option E: Option E is incorrect because JAK inhibitors such as tofacitinib are not preferred in pregnancy and carry their own reproductive safety concerns; oral administration does not protect the fetus.

4. Adalimumab is a fully human anti-TNF monoclonal antibody used in both Crohn's disease and ulcerative colitis. By what route is adalimumab administered for maintenance therapy?

A) Intravenous infusion at an infusion center every 8 weeks
B) Oral tablet taken twice daily
C) Intramuscular injection administered monthly in clinic
D) Intravenous induction followed by intranasal maintenance
E) Subcutaneous self-injection, typically 40 mg every 2 weeks after induction

ANSWER: E

Rationale:

Adalimumab is administered subcutaneously, with a typical regimen of 160 mg at week 0, 80 mg at week 2, then 40 mg every 2 weeks for maintenance. The subcutaneous route allows patient self-injection at home, offering convenience but requiring the patient to be willing and able to self-administer.

Option A: Option A describes infliximab, which is given by intravenous infusion and does require infusion center visits.
Option B: Option B describes the JAK inhibitors, which are oral small molecules; adalimumab is a protein antibody and cannot be given orally.
Option C: Option C is incorrect because adalimumab is not given intramuscularly.
Option D: Option D is incorrect; adalimumab is not given intravenously or intranasally.

5. Janus kinase (JAK) inhibitors differ fundamentally from the biologic agents used in inflammatory bowel disease. Which set of properties correctly distinguishes JAK inhibitors from monoclonal antibody biologics?

A) They are infused proteins that require latent tuberculosis screening before every dose
B) They are injectable antibodies that develop neutralizing anti-drug antibodies over time
C) They are oral small molecules that act intracellularly and, because they are not proteins recognized by the immune system, do not provoke anti-drug antibody formation
D) They are gut-selective agents that block lymphocyte trafficking to the intestinal mucosa
E) They are weight-based intravenous antibodies directed at the IL-12/IL-23 p40 subunit

ANSWER: C

Rationale:

JAK inhibitors are oral small-molecule immunosuppressants that block intracellular JAK-STAT signaling downstream of multiple cytokine receptors. Because they are small molecules rather than proteins, the immune system does not recognize them as foreign, so they do not generate anti-drug antibodies; this lack of immunogenicity is a practical advantage in patients who have lost response to multiple biologics.

Option A: Option A describes infused biologics such as infliximab; JAK inhibitors are oral.
Option B: Option B incorrectly states that JAK inhibitors develop neutralizing anti-drug antibodies; JAK inhibitors specifically do not generate anti-drug antibodies.
Option D: Option D describes vedolizumab, a gut-selective biologic.
Option E: Option E describes ustekinumab, an intravenous/subcutaneous antibody, not a JAK inhibitor.

6. Vedolizumab is described as a gut-selective biologic. What is its molecular target?

A) The p40 subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23)
B) The alpha-4-beta-7 integrin on gut-homing lymphocytes, blocking their interaction with mucosal addressin cell adhesion molecule-1 (MAdCAM-1) on intestinal vascular endothelium
C) Soluble and transmembrane TNF-alpha
D) The intracellular Janus kinase (JAK)-STAT signaling cascade
E) The interleukin-23 (IL-23) p19 subunit

ANSWER: B

Rationale:

Vedolizumab is a humanized monoclonal antibody that selectively blocks the alpha-4-beta-7 integrin on gut-homing lymphocytes, preventing their interaction with MAdCAM-1 on intestinal vascular endothelium and thereby blocking lymphocyte trafficking into the gut mucosa. Because this integrin is expressed predominantly on gut-homing rather than systemic lymphocytes, the effect is compartmentalized to the intestine.

Option A: Option A describes ustekinumab.
Option C: Option C describes the anti-TNF agents.
Option D: Option D describes the JAK inhibitors.
Option E: Option E describes risankizumab. None of these is the vedolizumab target.

7. Ustekinumab is approved for both Crohn's disease and ulcerative colitis. Which cytokine target correctly describes its mechanism of action?

A) The alpha-4-beta-7 integrin on gut-homing lymphocytes
B) Soluble and transmembrane TNF-alpha
C) The interleukin-23 (IL-23) p19 subunit only, sparing interleukin-12 (IL-12)
D) The p40 subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23), blocking both cytokines
E) The intracellular Janus kinase 1 (JAK1) enzyme

ANSWER: D

Rationale:

Ustekinumab binds the p40 subunit that is shared by IL-12 and IL-23, thereby blocking both cytokines. IL-12 drives Th1 differentiation and interferon-gamma production, while IL-23 maintains and amplifies Th17 cells; blocking the common p40 subunit inhibits both pathways.

Option A: Option A describes vedolizumab.
Option B: Option B describes the anti-TNF agents.
Option C: Option C describes risankizumab, which selectively blocks only the IL-23 p19 subunit and spares IL-12; this is the key distinction from ustekinumab.
Option E: Option E describes a JAK inhibitor, an intracellular small molecule rather than an antibody.

8. Before initiating any anti-TNF agent, a specific infectious screening step is mandatory because TNF-alpha is essential for maintaining the integrity of granulomas. Which screening is required, and what is the underlying reason?

A) Screening for latent tuberculosis, because TNF-alpha maintains granuloma integrity and its neutralization can release viable mycobacteria, causing reactivation
B) Screening for latent malaria, because anti-TNF therapy reactivates dormant liver-stage parasites
C) Screening for Clostridioides difficile colonization, because anti-TNF agents promote toxin production
D) Screening for prior herpes zoster, because anti-TNF therapy is the leading cause of zoster reactivation
E) Screening for venous thromboembolism, because anti-TNF agents carry a black box warning for clot formation

ANSWER: A

Rationale:

Reactivation of latent tuberculosis is the most important infectious risk of anti-TNF therapy. TNF-alpha is required to maintain the granulomas that wall off latent Mycobacterium tuberculosis; neutralizing TNF can break down those granulomas and release viable organisms. All patients must be screened with a tuberculin skin test and/or interferon-gamma release assay plus chest X-ray, and latent tuberculosis must be treated before starting therapy.

Option B: Option B fabricates a malaria reactivation risk; anti-TNF agents are not associated with malaria reactivation.
Option C: Option C is incorrect; this is not a standard pre-biologic screen tied to granuloma biology.
Option D: Option D misattributes the prominent zoster reactivation risk, which belongs to the JAK inhibitors rather than anti-TNF agents.
Option E: Option E misattributes the venous thromboembolism black box warning, which applies to JAK inhibitors, not anti-TNF agents.

9. Therapeutic drug monitoring (TDM) of biologic agents in inflammatory bowel disease guides dose optimization and loss-of-response management. What two measurements form the basis of TDM?

A) Serum C-reactive protein and fecal calprotectin
B) Complete blood count and liver function tests
C) Serum trough drug concentration and anti-drug antibody (ADA) level
D) Erythrocyte sedimentation rate and serum albumin
E) Peak serum drug concentration measured 1 hour after dosing and urinary drug clearance

ANSWER: C

Rationale:

Therapeutic drug monitoring of biologics is based on measuring the serum trough drug concentration (the lowest level, drawn immediately before the next scheduled dose) together with the anti-drug antibody level. Together these distinguish the mechanisms of loss of response and guide whether to dose-escalate, switch agent, or switch class.

Option A: Option A misidentifies inflammatory biomarkers that are interpreted alongside TDM but are not the drug-level measurements that define it.
Option B: Option B misidentifies general safety labs, which are not TDM parameters.
Option D: Option D misidentifies nonspecific inflammatory and nutritional markers, which are not TDM parameters.
Option E: Option E is incorrect because TDM uses trough rather than peak levels, and these biologics are cleared by reticuloendothelial catabolism rather than measured by urinary clearance.

10. Vedolizumab does not require latent tuberculosis screening and does not increase systemic serious infection rates. What property of its mechanism explains this favorable infection profile?

A) It is cleared so rapidly that immunosuppression is never sustained long enough to matter
B) It stimulates rather than suppresses systemic immune surveillance
C) It is co-administered with an antimicrobial that offsets infection risk
D) It blocks TNF-alpha only at the site of active inflammation, sparing systemic TNF
E) The alpha-4-beta-7 integrin it targets is expressed predominantly on gut-homing lymphocytes, so its immunosuppressive effect is compartmentalized to the gut and systemic immune surveillance is largely preserved

ANSWER: E

Rationale:

Vedolizumab targets the alpha-4-beta-7 integrin, which is expressed predominantly on gut-homing memory T cells rather than on systemic lymphocytes. Blocking trafficking to the intestinal mucosa therefore produces an immunosuppressive effect that is compartmentalized to the gut while largely preserving systemic immune surveillance. This is why vedolizumab does not require tuberculosis screening and does not raise systemic serious infection rates, making it preferred in patients at elevated infection risk.

Option A: Option A is incorrect; the favorable profile is due to gut selectivity, not rapid clearance.
Option B: Option B incorrectly states that vedolizumab stimulates immune surveillance; vedolizumab suppresses gut lymphocyte trafficking rather than stimulating immunity.
Option C: Option C fabricates a co-administered antimicrobial that does not exist.
Option D: Option D incorrectly describes vedolizumab as an anti-TNF agent; it does not act on TNF-alpha at all.

11. In 2022 the U.S. Food and Drug Administration (FDA) issued a class-wide black box warning for Janus kinase (JAK) inhibitors based on the ORAL Surveillance trial. Which statement correctly summarizes that warning and its clinical implication?

A) JAK inhibitors are first-line therapy in all inflammatory bowel disease patients because of their oral convenience
B) JAK inhibitors carry increased risk of major adverse cardiovascular events, venous thromboembolism, and malignancy compared with TNF inhibitors, and should generally be reserved for patients with an inadequate response to or intolerance of one or more TNF inhibitors
C) JAK inhibitors are contraindicated in all patients under age 50 regardless of risk factors
D) The warning applies only to tofacitinib and not to other JAK inhibitors such as upadacitinib or filgotinib
E) The warning establishes that JAK inhibitors reduce cardiovascular events relative to anti-TNF agents

ANSWER: B

Rationale:

The class-wide black box warning, prompted by the ORAL Surveillance trial, identifies an increased risk of major adverse cardiovascular events, venous thromboembolism, malignancy, and serious infections with JAK inhibitors compared with TNF inhibitors, particularly in patients aged 50 or older with cardiovascular risk factors. The practical consequence is that JAK inhibitors should generally be used only after inadequate response to or intolerance of one or more TNF inhibitors.

Option A: Option A incorrectly states that JAK inhibitors are first-line in all patients, which is the opposite of the warning's intent.
Option C: Option C overstates the warning; it does not impose an absolute contraindication for everyone under 50, but rather emphasizes risk in older patients with additional risk factors.
Option D: Option D is incorrect because the warning is class-wide and explicitly applies to upadacitinib and filgotinib as well.
Option E: Option E inverts the actual finding, which showed increased rather than decreased cardiovascular risk.

12. Combining an anti-TNF biologic with an immunomodulator such as azathioprine or 6-mercaptopurine improves long-term outcomes in inflammatory bowel disease. What is the principal pharmacological reason this combination is used?

A) The immunomodulator directly neutralizes additional TNF-alpha, doubling the anti-inflammatory effect
B) The immunomodulator accelerates clearance of the biologic, requiring less frequent dosing
C) The immunomodulator provides gut-selective targeting that the biologic lacks
D) The immunomodulator reduces formation of anti-drug antibodies against the biologic, raising trough drug concentrations and improving durability of response
E) The immunomodulator prevents reactivation of latent tuberculosis during biologic therapy

ANSWER: D

Rationale:

Adding a thiopurine immunomodulator reduces the formation of anti-drug antibodies against the biologic, which raises trough drug concentrations and improves long-term clinical outcomes; this benefit was shown for infliximab in SONIC and for adalimumab in DIAMOND.

Option A: Option A is incorrect; thiopurines do not neutralize TNF-alpha.
Option B: Option B incorrectly states that the immunomodulator accelerates clearance; reducing immunogenicity tends to maintain rather than accelerate drug clearance.
Option C: Option C is incorrect; thiopurines are not gut-selective.
Option E: Option E is incorrect; thiopurines do not prevent tuberculosis reactivation, and combination immunosuppression actually increases opportunistic infection risk.

13. A patient maintained on infliximab for 18 months gradually loses clinical response. Testing shows a low trough drug concentration with high anti-drug antibody titers. How does infliximab's molecular structure relate to this outcome?

A) Its chimeric structure, with a murine component, makes it more immunogenic than fully human agents, and anti-drug antibodies against that murine portion are the primary mechanism of secondary loss of response
B) Its fully human structure makes anti-drug antibody formation essentially impossible, so the result must be a laboratory error
C) Its lack of a fragment crystallizable (Fc) region prevents complement fixation and explains the loss of response
D) Its small-molecule structure allows it to be metabolized by hepatic cytochrome enzymes, lowering the trough level
E) Its gut-selective integrin binding is saturated, so additional drug cannot bind

ANSWER: A

Rationale:

Infliximab is a chimeric antibody containing a murine component, which makes it more immunogenic than fully human anti-TNF agents. Anti-drug antibodies directed against that murine portion are the primary mechanism of secondary loss of response, producing exactly the picture described: low trough concentration with high anti-drug antibody titers.

Option B: Option B is incorrect because infliximab is chimeric, not fully human, and is in fact among the more immunogenic agents.
Option C: Option C describes certolizumab's missing Fc region, which is unrelated to this immunogenic loss of response.
Option D: Option D is incorrect because infliximab is a large antibody cleared by reticuloendothelial catabolism, not a small molecule metabolized by cytochrome enzymes.
Option E: Option E describes an integrin-blocking mechanism that infliximab does not possess.

14. Risankizumab selectively blocks the interleukin-23 (IL-23) p19 subunit rather than the shared p40 subunit. What is the pharmacological rationale for sparing interleukin-12 (IL-12)?

A) IL-12 is the dominant driver of mucosal inflammation, so blocking it would worsen disease
B) IL-12 blockade is what causes the cardiovascular black box warning, which selective agents avoid
C) The Th17 pathway driven by IL-23 is the dominant pathological mechanism in inflammatory bowel disease, so selective p19 blockade is sufficient while preserving IL-12-dependent protective immunity, including antiviral and antimycobacterial responses
D) IL-12 cannot be targeted by monoclonal antibodies because it lacks an extracellular domain
E) Sparing IL-12 allows the drug to be administered orally rather than by injection

ANSWER: C

Rationale:

The rationale for selective IL-23 p19 blockade rests on the observation that the IL-23-driven Th17 pathway, rather than the IL-12-driven Th1 pathway, is the dominant pathological mechanism in inflammatory bowel disease. Blocking p19 is therefore pharmacologically sufficient, while preserving IL-12 maintains protective immunity, including antiviral and antimycobacterial defenses.

Option A: Option A inverts the pathophysiology; IL-23/Th17, not IL-12, is dominant.
Option B: Option B fabricates a link between IL-12 blockade and the cardiovascular warning; the JAK inhibitor cardiovascular warning is unrelated to IL-12 blockade.
Option D: Option D incorrectly states that IL-12 cannot be targeted by antibodies; IL-12 is a secreted cytokine readily targeted by antibodies such as ustekinumab.
Option E: Option E is incorrect; risankizumab is an injectable antibody, and IL-12 sparing has nothing to do with route of administration.

15. Upadacitinib is described as a selective Janus kinase 1 (JAK1) inhibitor. What was the design rationale for JAK1 selectivity relative to a pan-JAK agent?

A) JAK1 selectivity eliminates the cardiovascular black box warning entirely
B) JAK1 selectivity was intended to reduce Janus kinase 2 (JAK2)-mediated adverse effects such as anemia and neutropenia while preserving efficacy through JAK1-dependent cytokine pathway blockade
C) JAK1 selectivity converts the drug from an oral agent into a gut-selective biologic
D) JAK1 selectivity allows the drug to neutralize TNF-alpha in addition to blocking cytokine signaling
E) JAK1 selectivity prevents the formation of anti-drug antibodies, which pan-JAK agents otherwise generate

ANSWER: B

Rationale:

JAK2 mediates erythropoietin and related signaling, so JAK2 inhibition contributes to anemia and neutropenia. Upadacitinib's JAK1 selectivity was designed to reduce these JAK2-mediated adverse effects while preserving efficacy through JAK1-dependent cytokine pathway blockade.

Option A: Option A is incorrect; the cardiovascular black box warning is class-wide and applies to upadacitinib despite its selectivity.
Option C: Option C is incorrect; selectivity does not change it into a gut-selective biologic, and it remains an oral small molecule.
Option D: Option D is incorrect because JAK inhibitors do not neutralize TNF-alpha.
Option E: Option E is incorrect; JAK inhibitors as a class lack immunogenicity because they are small molecules, so this is not a consequence of JAK1 selectivity specifically.

16. A recognized adverse effect occurs at higher rates with Janus kinase (JAK) inhibitors than with biologics or conventional immunomodulators, prompting a specific vaccination recommendation. Which adverse effect and preventive measure correctly pair together?

A) Latent tuberculosis reactivation, prevented by isoniazid before therapy
B) Hepatitis B reactivation, prevented by antiviral prophylaxis
C) Hepatosplenic T-cell lymphoma, prevented by withdrawing thiopurines
D) Anti-drug antibody formation, prevented by adding an immunomodulator
E) Herpes zoster reactivation, for which the recombinant zoster vaccine should be given before or as early as possible after starting therapy

ANSWER: E

Rationale:

Herpes zoster reactivation occurs at notably higher rates with JAK inhibitors than with biologics or conventional immunomodulators. Because of this, the recombinant zoster vaccine should be administered before, or as early as possible after, starting JAK inhibitor therapy.

Option A: Option A describes a risk and preventive step specific to anti-TNF agents, not the characteristic JAK inhibitor signal.
Option B: Option B describes anti-TNF–associated hepatitis B reactivation management, not the characteristic JAK inhibitor signal.
Option C: Option C describes a rare risk of long-term combination anti-TNF plus thiopurine therapy, not the JAK inhibitor zoster signal.
Option D: Option D describes immunogenicity of biologics, which JAK inhibitors do not exhibit.

17. A patient on an anti-TNF biologic loses response. Therapeutic drug monitoring shows a low trough drug concentration with high anti-drug antibody (ADA) titers. Using the framework established earlier in this set, how is this pattern classified and managed?

A) Immunogenic failure; the appropriate step is to switch to a different anti-TNF agent or to a different class of biologic
B) Pharmacokinetic failure; the appropriate step is simply to increase the dose of the current agent
C) Pharmacodynamic failure; the appropriate step is to continue the same agent at the same dose
D) Primary non-response; the appropriate step is to stop all advanced therapy
E) Laboratory artifact; the appropriate step is to ignore the result and continue unchanged

ANSWER: A

Rationale:

A low trough concentration with high anti-drug antibodies defines immunogenic failure: the patient has mounted an antibody response that clears the drug. Dose escalation is not reliable here because the antibodies will continue to neutralize drug; the appropriate step is to switch to a different anti-TNF agent or to a different biologic class.

Option B: Option B describes the management of pharmacokinetic failure, which is the low-trough/low-ADA pattern, not this one.
Option C: Option C misidentifies the scenario as pharmacodynamic failure; pharmacodynamic failure is defined by an adequate trough, not a low trough with high ADA.
Option D: Option D is incorrect because this is secondary loss of response, not primary non-response, and stopping all therapy is not indicated.
Option E: Option E is incorrect; the result is informative and should guide a class or agent switch.

18. A different patient on an anti-TNF biologic loses response, but therapeutic drug monitoring shows an adequate trough drug concentration with no significant anti-drug antibodies. Applying the same framework, what does this pattern indicate and how should it be managed?

A) Pharmacokinetic failure; shorten the dosing interval to raise the trough
B) Immunogenic failure; add an immunomodulator to suppress antibody formation
C) Primary non-response; the patient never responded and should have therapy withdrawn entirely
D) Pharmacodynamic failure (a shift in disease mechanism); switch to a biologic of a different class rather than dose-escalating, because more of the same drug will not overcome a mechanism that is no longer TNF-driven
E) Subtherapeutic dosing; double the dose of the current agent

ANSWER: D

Rationale:

An adequate trough with loss of response indicates pharmacodynamic failure: the inflammation is no longer driven by the targeted pathway, so adding more of the same drug will not help. The correct step is to switch to a biologic of a different class.

Option A: Option A is incorrect because the trough is already adequate, so there is no pharmacokinetic deficit to correct by shortening the interval.
Option B: Option B is incorrect because there are no significant anti-drug antibodies, so this is not immunogenic failure.
Option C: Option C misidentifies secondary loss of response as primary non-response and inappropriately abandons all therapy.
Option E: Option E is incorrect because escalating a drug that already has adequate levels will not overcome a mechanism shift.

19. A patient with Crohn's disease started on an anti-TNF agent at standard induction doses shows no meaningful response by week 12. This is primary non-response. What does this finding imply about the patient's inflammation, and what is the appropriate next step?

A) Tumor necrosis factor (TNF) is the dominant driver but the dose was too low; escalate the anti-TNF dose
B) The patient has developed anti-drug antibodies; add an immunomodulator and continue the same agent
C) TNF is not the dominant driver of inflammation in this patient; switch to a biologic with a different mechanism such as vedolizumab, ustekinumab, or a Janus kinase (JAK) inhibitor rather than optimizing the anti-TNF dose
D) The diagnosis must be incorrect; discontinue all therapy pending re-evaluation
E) The patient should remain on the anti-TNF agent indefinitely because response is merely delayed in all such cases

ANSWER: C

Rationale:

Primary non-response to an anti-TNF agent indicates that TNF is not the dominant driver of inflammation in that patient. Because the pathway being targeted is not the operative one, the appropriate strategy is to switch to a biologic with a different mechanism rather than optimizing the anti-TNF dose.

Option A: Option A is incorrect because escalating a drug aimed at the wrong pathway does not address the underlying problem.
Option B: Option B is incorrect because primary non-response is not an immunogenicity phenomenon, and adding an immunomodulator to the same ineffective mechanism does not help.
Option D: Option D overstates the implication; primary non-response does not by itself mean the diagnosis is wrong, and abandoning all therapy is inappropriate.
Option E: Option E incorrectly states that response is merely delayed in all such cases; not all patients have delayed response, and persisting with an ineffective mechanism wastes time.

20. A 74-year-old patient with moderate to severe ulcerative colitis and a history of recurrent serious infections requires advanced therapy. Applying the infection-risk principles established earlier in this set, which biologic is generally preferred in this setting?

A) Infliximab, because intravenous dosing gives the most reliable response in elderly patients
B) Vedolizumab, because its gut-selective mechanism preserves systemic immune surveillance and is associated with a favorable infection profile, making it preferred in elderly or high-infection-risk patients
C) Tofacitinib, because its oral route avoids any infection risk
D) A combination of an anti-TNF agent plus azathioprine, to maximize efficacy
E) Adalimumab, because subcutaneous administration reduces systemic infection risk

ANSWER: B

Rationale:

Vedolizumab's gut-selective alpha-4-beta-7 blockade compartmentalizes immunosuppression to the intestine and preserves systemic immune surveillance, giving it a favorable systemic infection profile. This makes it the preferred biologic in elderly patients and others at elevated infection risk.

Option A: Option A is incorrect; the intravenous route does not mitigate the systemic infection risk of anti-TNF therapy.
Option C: Option C is incorrect because JAK inhibitors carry a black box warning that includes serious infections and are not low-risk in older patients; the oral route does not eliminate infection risk.
Option D: Option D incorrectly recommends maximizing immunosuppression and therefore infection risk, which is the opposite of what this patient needs.
Option E: Option E is incorrect; the subcutaneous route does not reduce the systemic infection risk inherent to TNF neutralization.

21. A pregnant patient in her third trimester has Crohn's disease that requires continued anti-TNF therapy. Drawing on the structural principles covered earlier in this set, which agent is preferred and why?

A) Infliximab, because intravenous dosing allows the level to be timed away from delivery
B) Adalimumab, because its fully human structure prevents placental transfer
C) Golimumab, because monthly dosing limits total fetal exposure
D) Upadacitinib, because oral agents do not reach the fetal circulation
E) Certolizumab pegol, because it is a Fab' fragment lacking the fragment crystallizable (Fc) region and therefore does not cross the placenta via the neonatal Fc receptor

ANSWER: E

Rationale:

Certolizumab pegol lacks the Fc region required for neonatal Fc receptor–mediated placental transfer, so it does not appreciably cross the placenta and is preferred when anti-TNF therapy must continue into the third trimester.

Option A: Option A is incorrect because infliximab is a full IgG1 antibody that crosses the placenta in the third trimester regardless of infusion timing.
Option B: Option B is incorrect because adalimumab, although fully human, is a complete IgG1 antibody that does transfer across the placenta.
Option C: Option C is incorrect because golimumab is also a full IgG1 antibody and its dosing interval does not prevent transfer.
Option D: Option D is incorrect because JAK inhibitors are not preferred in pregnancy and carry their own reproductive concerns; oral administration does not protect the fetus.

22. A 58-year-old patient with ulcerative colitis, hypertension, and a prior myocardial infarction asks specifically about an oral agent after inadequate response to a TNF inhibitor. Applying the black box warning principles established earlier in this set, how should a Janus kinase (JAK) inhibitor be approached in this patient?

A) With caution; this patient is aged 50 or older with cardiovascular risk factors, the population in which the black box warning identifies the greatest risk of major adverse cardiovascular events, so the decision requires careful risk-benefit assessment and acknowledgment that he falls into the higher-risk group even though prior TNF inhibitor failure makes a JAK inhibitor a candidate option
B) Without any reservation, because oral agents are uniformly safer than biologics
C) As absolutely contraindicated in all patients who have ever had hypertension
D) As first-line therapy ahead of any biologic, because of the convenience of oral dosing
E) Only if combined with an anti-TNF agent to offset cardiovascular risk

ANSWER: A

Rationale:

This patient is aged 50 or older with established cardiovascular risk factors and prior myocardial infarction, placing him squarely in the population for whom the black box warning identifies the greatest risk of major adverse cardiovascular events, venous thromboembolism, and malignancy. Prior TNF inhibitor failure does make a JAK inhibitor a candidate, but the decision demands careful risk-benefit assessment and explicit acknowledgment of his elevated risk.

Option B: Option B is incorrect because oral agents are not uniformly safer; the warning exists precisely because of elevated risk in this group.
Option C: Option C overstates the warning into an absolute contraindication, which it is not.
Option D: Option D incorrectly recommends JAK inhibitors as first-line ahead of biologics, which contradicts the warning's directive to reserve them for use after inadequate response to TNF inhibitors.
Option E: Option E incorrectly recommends combining a JAK inhibitor with an anti-TNF agent, which compounds immunosuppression and does not offset cardiovascular risk.